UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
PURSUANT TO SECTION 13 OR 15(d)
OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): January 20, 2005
Anika Therapeutics, Inc.
(Exact Name of Registrant as Specified in Its Charter)
|
Massachusetts |
|
000-21326 |
|
04-3145961 |
|
(State or Other Jurisdiction of Incorporation) |
|
(Commission File |
|
(I.R.S. Employer Identification No.) |
|
|
|
|
|
|
|
160 New Boston Street, Woburn, Massachusetts |
|
01801 |
||
|
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
No Change Since Last Report
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01: Entry Into a Material Definitive Agreement.
On January 20, 2005 and January 21, 2005, the Compensation Committee of the Board of Directors of the Registrant increased the annual salary of our named executive officers as follows:
|
|
|
2005 Salary |
|
Increase from |
|
||
|
Charles H. Sherwood |
|
$ |
375,000 |
|
$ |
15,000 |
|
|
Frank Luppino |
|
$ |
196,300 |
|
$ |
21,300 |
|
|
James E. O’Neill |
|
$ |
121,679 |
|
$ |
4,679 |
|
Also, at the same time the Compensation Committee exercised its discretion to approve cash bonus payments in respect of services rendered by its officers during 2004 to executive officers in the following amounts set forth below opposite the name of such officer:
|
Charles H. Sherwood |
|
$ |
180,000 |
|
|
Frank Luppino |
|
$ |
43,750 |
|
|
James E. O’Neill |
|
$ |
17,550 |
|
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
|
|
ANIKA THERAPEUTICS, INC. |
||
|
|
|
||
|
January 26, 2005 |
By: |
/s/ Charles H. Sherwood |
|
|
|
|
Charles H. Sherwood, Ph.D. |
|
|
|
|
Chief Executive Officer and President |
|
3